Par Pharma (PRX) Continuing Higher on Drug News, 3 Analyst Upgrades

Shares of Par Pharma (NYSE: PRX) are continuing higher today, even in light of yesterday's late-day 13% rally. The stock is currently up about 3% to $20.32 amid drug news and numerous analyst upgrades.

Between yesterday's close and this morning's open, Par announced that it received final approval to market the generic version of Catapres TTS(R) and also that the FDA accepted its application for Miconazole Lauriad(R). On the analyst front, we have:

• Goldman upgrading the stock from Sell to Neutral, with an $18 price target,
  
• Caris & Co. raising shares from Above Average to Buy, and
  
• Buckingham upgrading the stock from Neutral to Accumulate.

You May Also Be Interested In

• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
• Veeva Systems names Dan Rizzo EVP of sales amid leadership change
• Freedom Broker Upgrades Taylor Devices, Inc. (TAYD) to Buy